Clinical Trials · NCT05709444
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Palatin Technologies, Inc
- Enrollment
- 16
- Start date
- Dec 2022
- Locations
- 9 sites, United States
- Primary endpoint
- To demonstrate the efficacy of 0.5 mg subcutaneous BMT (given twice a day), used in combination with a subject's maximum tolerated dose of RAAS inhibition therapy, reduces urinary protein by 50% from baseline UP/Cr levels.